BIIB Add to watchlist
$190.07 +4.12 (+2.22%)
After Hours: $190.07 +0.00 (+0.00%)
Last updated: Apr 22, 2026 20:26
52-Week Range
$190.07
$115.25 $190.07 $202.41

Fundamentals Overview

Biogen Inc. is near the high of its 52-week range with moderate valuation, trending upward today.

Valuation moderate

P/E 21.6 P/B 1.53 P/S 2.84

Intrinsic value (DCF)

+296.6% upside vs price

Profitability

Net margin 13.2%

Risk (Beta)

0.16 — lower vol

Earnings & growth

EPS $8.82 Rev -7.1% Profit -110.4% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 80% confidence Risk: Lower Volatility — Beta 0.16. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +296.6% upside vs price · Analyst grade: A- · Sentiment improving (2 upgrades) · 3M vs S&P 500: +10% · 3M vs Healthcare sector: +20.7%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$27.89B
P/E (TTM)
21.56
EPS (TTM)
$8.82
Dividend Yield
N/A
52-Week Range
$115.25 - $202.41
Volume vs Avg
N/A
Beta
0.16

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB...
Sector: Healthcare
Headquarters: US
Employees: 7,605
IPO Date: Sep 1991
Beta: 0.16 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A-. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 6, Equal Weight: 4, Hold: 4, Market Perform: 1, Neutral: 8, Outperform: 3, Overweight: 2, Reduce: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $753.73; current price is $190.07. That’s a +296.6% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 21.56
DCF value (model) $753.73 (296.6% upside)
PEG (TTM) N/A
P/B (TTM) 1.53
P/S (TTM) 2.84
P/FCF (TTM) 13.04
Liquidity & enterprise
Current Ratio (TTM) 2.68
Quick Ratio (TTM) 2.03
Cash Ratio (TTM) 0.9
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 13.18%
Gross margin (TTM) 70.47%
Operating margin (TTM) 19.14%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for BIIB.

Analyst Sentiment at a Glance

A- Sentiment Improving
Buy 6Equal Weight 4Hold 4Market Perform 1Neutral 8Outperform 3Overweight 2Reduce 2
2 upgrades, 1 downgrade
Price Target Consensus
Current $190.07
Median $219.50
Consensus $212.45
Low consensus $143.00
High consensus $250.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Wells Fargo upgrade Equal Weight Overweight 2026-04-20
Piper Sandler upgrade Neutral Overweight 2026-04-14
Citigroup maintain Neutral Neutral 2026-04-13
Truist Securities maintain Hold Hold 2026-04-13
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-10
HC Wainwright & Co. maintain Buy Buy 2026-04-02
Canaccord Genuity maintain Buy Buy 2026-04-01
Oppenheimer maintain Outperform Outperform 2026-04-01
HSBC maintain Reduce Reduce 2026-03-17
Freedom Broker maintain Hold Hold 2026-02-23
Wedbush maintain Neutral Neutral 2026-02-10
Piper Sandler maintain Neutral Neutral 2026-02-09
Truist Securities maintain Hold Hold 2026-02-09
BMO Capital maintain Market Perform Market Perform 2026-02-09
TD Cowen maintain Buy Buy 2026-02-09
RBC Capital maintain Outperform Outperform 2026-02-09
JP Morgan maintain Neutral Neutral 2026-02-09
Wells Fargo maintain Equal Weight Equal Weight 2026-02-09
HC Wainwright & Co. maintain Buy Buy 2026-02-09
Guggenheim maintain Buy Buy 2026-02-09
Canaccord Genuity maintain Buy Buy 2026-02-09
Wedbush maintain Neutral Neutral 2026-02-09
Citigroup maintain Neutral Neutral 2026-02-09
Oppenheimer maintain Outperform Outperform 2026-01-30
Citigroup maintain Neutral Neutral 2026-01-27
Truist Securities maintain Hold Hold 2026-01-08
Citigroup maintain Neutral Neutral 2026-01-07
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-12
HSBC downgrade Hold Reduce 2025-12-10
Wells Fargo maintain Equal Weight Equal Weight 2025-12-10